A NEW ARTIFICIAL CORNEAL PROSTHESIS (KPRO)

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43EY014079-01
Agency Tracking Number: EY014079
Amount: $97,841.00
Phase: Phase I
Program: SBIR
Awards Year: 2002
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
TAMCENAN CORPORATION
TAMCENAN CORPORATION, 1703 S MINNESOTA AVE, SIOUX FALLS, SD, 57105
DUNS: N/A
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 THOMAS WHITE
 (605) 334-7715
 TWHITE@USD.EDU
Business Contact
 THOMAS WHITE
Phone: (605) 334-0113
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): About 4 to 8 thousand people yearly in the U.S. suffer blinding corneal disease not amenable to conventional keratoplasty. The improved keratoprosthesis (KPro) may restore functional vision for these people, and is the basis for a significant demand supporting commercialization. This Phase I project involves developing an improved thinner KPro of PMMA that, with a significant innovative process, can be more securely fixated to a donor cornea for use as a standard graft. The measurable goals are: 1) developing a KPro production methodology to produce powers within +0.5D accuracy; 2) demonstration of the fusion of front and back flanges with a narrow gap of 0.5-0.7mm with strength of 50 Newtons; 3) an independent laboratory determination of bioburden and ethylene oxide sterilization validation, and toxicology testing. Reaching these endpoints will permit processing directly to a Clinical Trial in Phase II project under FDA Guidance Document for Keratoprostheses. Tamcenan Corporation, and the Principle Investigator have experience in developing and securing regulatory clearence and comericalization of ophthalmic implants. Engineering & Ophthalmic Services has experience in devising manufacturing protocols for contact lenses and Kpros. Geneva Laboratories, Inc. is a full service certified testing laboratory that follows accepted protocols for required tests. PROPOSED COMMERCIAL APPLICATION: The estimated 4 to 8 thousand patients in the U.S. yearly that cannot be adequately served by standard keratoplasty or existing KPros form a significant market for commercialization of a product that costs between $500.00 and $1000.00. The participation of Eye Banks in this project will aid distribution and increase rewards for those participating.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government